CureVac (CVAC) Competitors $5.40 -0.01 (-0.09%) As of 07/3/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CVAC vs. ADMA, AKRO, PCVX, RYTM, KRYS, CYTK, ZLAB, PTCT, MRUS, and ACLXShould you be buying CureVac stock or one of its competitors? The main competitors of CureVac include ADMA Biologics (ADMA), Akero Therapeutics (AKRO), Vaxcyte (PCVX), Rhythm Pharmaceuticals (RYTM), Krystal Biotech (KRYS), Cytokinetics (CYTK), Zai Lab (ZLAB), PTC Therapeutics (PTCT), Merus (MRUS), and Arcellx (ACLX). These companies are all part of the "pharmaceutical products" industry. CureVac vs. Its Competitors ADMA Biologics Akero Therapeutics Vaxcyte Rhythm Pharmaceuticals Krystal Biotech Cytokinetics Zai Lab PTC Therapeutics Merus Arcellx CureVac (NASDAQ:CVAC) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment. Do insiders and institutionals have more ownership in CVAC or ADMA? 17.3% of CureVac shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 2.2% of CureVac shares are held by company insiders. Comparatively, 3.5% of ADMA Biologics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media refer more to CVAC or ADMA? In the previous week, ADMA Biologics had 9 more articles in the media than CureVac. MarketBeat recorded 10 mentions for ADMA Biologics and 1 mentions for CureVac. ADMA Biologics' average media sentiment score of 0.80 beat CureVac's score of -0.17 indicating that ADMA Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CureVac 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ADMA Biologics 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, CVAC or ADMA? CureVac has a beta of 2.53, indicating that its stock price is 153% more volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500. Do analysts rate CVAC or ADMA? CureVac presently has a consensus price target of $6.83, suggesting a potential upside of 26.66%. ADMA Biologics has a consensus price target of $27.67, suggesting a potential upside of 51.23%. Given ADMA Biologics' stronger consensus rating and higher probable upside, analysts clearly believe ADMA Biologics is more favorable than CureVac.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20ADMA Biologics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Is CVAC or ADMA more profitable? ADMA Biologics has a net margin of 45.01% compared to CureVac's net margin of 35.44%. ADMA Biologics' return on equity of 47.16% beat CureVac's return on equity.Company Net Margins Return on Equity Return on Assets CureVac35.44% 30.89% 25.54% ADMA Biologics 45.01%47.16%30.51% Which has stronger earnings & valuation, CVAC or ADMA? ADMA Biologics has lower revenue, but higher earnings than CureVac. CureVac is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCureVac$579.18M2.09$175.50M$0.925.86ADMA Biologics$426.45M10.24$197.67M$0.8521.52 SummaryADMA Biologics beats CureVac on 14 of the 17 factors compared between the two stocks. Get CureVac News Delivered to You Automatically Sign up to receive the latest news and ratings for CVAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CVAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CVAC vs. The Competition Export to ExcelMetricCureVacMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.22B$2.91B$5.54B$9.05BDividend YieldN/A2.44%5.24%4.02%P/E Ratio5.8621.5627.4320.23Price / Sales2.09281.76422.11118.64Price / Cash6.2442.7336.8958.07Price / Book1.617.518.045.67Net Income$175.50M-$55.05M$3.18B$249.13M7 Day Performance0.28%4.61%2.89%3.28%1 Month Performance20.96%4.72%3.70%5.56%1 Year Performance63.98%5.92%36.15%21.12% CureVac Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CVACCureVac4.6428 of 5 stars$5.40-0.1%$6.83+26.7%+72.9%$1.22B$579.18M5.86880ADMAADMA Biologics4.1158 of 5 stars$18.21+0.3%$27.67+51.9%+63.2%$4.35B$426.45M21.42530AKROAkero Therapeutics3.4701 of 5 stars$53.36-5.0%$82.50+54.6%+137.2%$4.25BN/A-27.3630Insider TradePCVXVaxcyte1.8029 of 5 stars$32.51-0.2%$136.50+319.9%-56.4%$4.19BN/A-8.15160News CoverageRYTMRhythm Pharmaceuticals3.8182 of 5 stars$63.19+0.7%$77.31+22.3%+61.2%$4.02B$136.86M-22.49140News CoverageKRYSKrystal Biotech4.5922 of 5 stars$137.46-1.0%$211.13+53.6%-19.5%$3.97B$333.45M33.04210News CoverageAnalyst RevisionCYTKCytokinetics3.9498 of 5 stars$33.04-0.4%$70.92+114.7%-37.7%$3.95B$18.47M-6.25250ZLABZai Lab3.4261 of 5 stars$34.97+0.7%$54.28+55.2%+111.6%$3.88B$398.99M-14.041,869Insider TradeAnalyst RevisionGap UpPTCTPTC Therapeutics4.316 of 5 stars$48.84-2.0%$65.00+33.1%+57.3%$3.87B$1.77B7.501,410Analyst RevisionMRUSMerus1.8673 of 5 stars$52.60-0.7%$84.64+60.9%+1.7%$3.64B$54.73M-12.8937ACLXArcellx2.9687 of 5 stars$65.85+0.8%$111.23+68.9%+23.0%$3.63B$107.94M-22.0280 Related Companies and Tools Related Companies ADMA Competitors AKRO Competitors PCVX Competitors RYTM Competitors KRYS Competitors CYTK Competitors ZLAB Competitors PTCT Competitors MRUS Competitors ACLX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CVAC) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CureVac N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share CureVac With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
